Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$72.79M+23764.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael A. Metzger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 298
- Beta
- 0.37
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.46
Financials
Revenue
$72.79M+23764.9%Net Income
$-49.36MEBITDA
$-36.68MFree Cash Flow
$-30.31MEPS (diluted)
$-0.55Shares Outstanding (diluted)
88.99M+397.2%Operating Expenses
$109.58MCash & Debt
$547.86MRevenue by Segment (annual)
$172.35MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $172.35M | $-285.42M | $-3.29 |
| 2024 | $23.68M | $-318.76M | $-3.73 |
| 2023 | $0.00 | $-209.36M | $-2.98 |
| 2022 | $0.00 | $-149.34M | $-2.46 |
| 2021 | $139.71M | $24.93M | $0.48 |
| 2020 | $1.52M | $-73.07M | $-1.77 |
| 2019 | $1.52M | $-55.95M | $-1.84 |
| 2018 | $1.52M | $-73.96M | $-2.92 |
| 2017 | $2.11M | $-60.80M | $-2.90 |
| 2016 | $1.22M | $-44.47M | $-3.04 |
| 2015 | $627.0K | $-24.12M | $-4.31 |
| 2014 | $0.00 | $-19.83M | $-2.07 |
| 2013 | $0.00 | $-14.17M | $-1.77 |
| 2012 | $0.00 | $-9.96M | $-0.14 |
Valuation
SNDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
117+133.33%Social Signal Score
Mentions (12)
- Newsgurufocus.com·3d ago·Negative
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
View source ↗ - Newsbusinesswire.com·3d ago·Negative
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsglobenewswire.com·5d ago·Positive
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company's first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME's annual list of the Best Inventions features 300 extrao…
View source ↗ - Newsbenzinga.com·7d ago·Negative
Syndax Pharmaceuticals Suffers Pipeline Blow Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial.
View source ↗ - Newsbenzinga.com·8d ago·Positive
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures gaining around 200 points on Tuesday. Shares of Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) fell sharply in pre-market trading after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.
View source ↗ - Newsglobenewswire.com·8d ago·Positive
…dvance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC). The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% o…
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases Syndax Pharmaceuticals remains a "Strong Buy," driven by label expansion and robust revenue growth for Revuforj and Niktimvo. Company achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Niktimvo, already approved for cGVHD, is being advanced into IPF and 1st-line cGVHD, with key phase 2 data readouts expected in Q4 2026.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
…vuforj. Recent SAVE trial data for Revuforj in AML shows 88% ORR and strong MRD negativity, derisking ongoing phase 3 trials and supporting expanding real-world use. SNDX's pipeline features next-gen menin and EGFR inhibitors, targeting high unmet needs in myelofibrosis and NSCLC, with rapid proof-of-concept timelines.
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, wit…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Syndax Announces Participation in September Investor Conferences NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
View source ↗
Earnings
Mon, Nov 2(in 12 days)
Consensus estimate $-0.48 per share
Typical surprise +5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.55 vs $-0.45miss
- Thu, Apr 30$-0.48 vs $-0.59beat
- Thu, Feb 26$-0.78 vs $-0.58miss
- Mon, Nov 3$-0.70 vs $-0.74beat
- Mon, Aug 4$-0.83 vs $-1.00beat
- Mon, May 5$-0.98 vs $-1.04beat
Estimates and results for SNDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SNDX officers and directors.
- Bought
- $267k
- Sold
- $8.4m
5 trades
21 trades
- Metzger Michael Asold
- Botwood Nicholas A.j.sold
- Botwood Nicholas A.j.sold
- Goldan Keith A.sold
- Metzger Michael Asold
- Metzger Michael Asold
- Goldan Keith A.sold
- Metzger Michael Asold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SNDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.